Maci 3CM x 5CM implant sheets
Ended Awarded Last action
- Contract number
- SPE2DR26FQQA7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $72,660
Award facts
- Contract value 100% obligated
- $72,659.87 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $72,659.87 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for MACI 3cm x 5cm implant sheets. The delivery order, issued on January 8, 2026, with an ultimate completion date of January 30, 2026, carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to provide Department of Defense healthcare facilities worldwide with a full range of pharmaceutical products and medical consumables.
DMS Pharmaceutical Group has demonstrated substantial performance as a critical supplier within the federal pharmaceutical supply chain, with numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division. The company's established product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, including specialty surgical products such as MACI implants. As one of multiple regional prime vendor contractors under the PPV-G GEN V program, DMS Pharmaceutical Group is positioned to support the recurring medical supply needs of military healthcare operations, with its indefinite delivery contract extending through December 31, 2036, and a ceiling value of $499,999,999.
Quick answers
Who was awarded contract SPE2DR26FQQA7?
SPE2DR26FQQA7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26FQQA7 worth?
The government has obligated $72,660 on SPE2DR26FQQA7.
Is contract SPE2DR26FQQA7 an order under another contract?
Yes. SPE2DR26FQQA7 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQQA7 competed?
The extent of competition for SPE2DR26FQQA7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award